Fiche du document
1 octobre 2020
- handle: 10670/1.uhl3na
- hal: hal-03088676
- doi: 10.1093/ije/dyaa128
- PUBMED: 32984907
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/ije/dyaa128
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32984907
Mots-clés
Cancer cure time to cure survival life expectancy population-based cancer registries Europe mixture cure models -bio]/Santé publique et épidémiologieSujets proches
Carcinoma Cancers Malignancy (Cancer) Malignant tumorsCiter ce document
Luigino Dal Maso et al., « Cancer cure for 32 cancer types: results from the EUROCARE-5 study », HAL-SHS : sociologie, ID : 10.1093/ije/dyaa128
Métriques
Partage / Export
Résumé
Background :Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period.Methods :7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15–74 years in 1990–2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%.Results :LEF ranged from 10 years for chronic lymphocytic leukaemia patients to 5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and